MedPath

Concordia Laboratories Inc.

🇱🇺Luxembourg
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 3
1 (33.3%)

Establishment of a PDT Patient Registry

Terminated
Conditions
Lung Cancer
First Posted Date
2018-07-17
Last Posted Date
2020-02-24
Lead Sponsor
Concordia Laboratories Inc.
Target Recruit Count
22
Registration Number
NCT03589456
Locations
🇺🇸

John Muir Clinical Research Center, Concord, California, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

and more 7 locations

Safety of PDT-Photofrin® Prior to Lung Surgery

Phase 1
Completed
Conditions
Lung Cancer
Lung Cancer Metastatic
Interventions
Device: Fiber optic
First Posted Date
2017-11-17
Last Posted Date
2020-01-13
Lead Sponsor
Concordia Laboratories Inc.
Target Recruit Count
10
Registration Number
NCT03344861
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

University of Colorado, Denver, Colorado, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 5 locations

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer

Phase 1
Completed
Conditions
Non-small Cell Lung Cancer (NSCLC)
Lung Metastasis
Interventions
Device: Fiber optic
First Posted Date
2016-09-27
Last Posted Date
2020-03-04
Lead Sponsor
Concordia Laboratories Inc.
Target Recruit Count
5
Registration Number
NCT02916745
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

🇺🇸

Southeastern Regional Medical Center, Atlanta, Georgia, United States

🇺🇸

Alexian Brothers Hospital Network, Elk Grove Village, Illinois, United States

and more 4 locations

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Phase 3
Terminated
Conditions
Hilar Cholangiocarcinoma
Interventions
Drug: Photodynamic therapy-Photofrin
Procedure: Stenting procedure
Drug: Chemotherapy regimen
First Posted Date
2014-03-10
Last Posted Date
2019-08-28
Lead Sponsor
Concordia Laboratories Inc.
Target Recruit Count
28
Registration Number
NCT02082522
Locations
🇺🇸

Western Regional Medical Center, Inc., Goodyear, Arizona, United States

🇺🇸

Mayo Clinic Cancer Center, Scottsdale, Arizona, United States

🇺🇸

University of Southern California Keck School of Medicine, Los Angeles, California, United States

and more 28 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.